Schroder Investment Management Group’s Apogee Therapeutics APGE Stock Holding History

Schroder Investment Management Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Sell	30,636 -66,020	-68%	-$5.95M	﹤0.01%	816
2026 Q1	$7.61M	Sell	96,656 -8,344	-8%	-$606K	0.01%	717
2025 Q4	$7.95M	Sell	105,000 -110,846	-51%	-$6.98M	0.01%	672
2025 Q3	$8.6M	Buy	215,846 +96,600	+81%	+$3.69M	0.01%	689
2025 Q2	$5.18M	Buy	119,246 +22,254	+23%	+$847K	﹤0.01%	761
2025 Q1	$3.85M	Buy	96,992 +38,526	+66%	+$1.49M	﹤0.01%	811
2024 Q4	$2.61M	Hold	58,466	–	–	﹤0.01%	881
2024 Q3	$3.39M	Sell	58,466 -54,392	-48%	-$2.61M	﹤0.01%	867
2024 Q2	$4.44M	Buy	+112,858	New	+$5.48M	﹤0.01%	802

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Schroder Investment Management Group's APGE Position: Q2 2026 in Review

Schroder Investment Management Group reduced its Apogee Therapeutics (APGE) stake by 68% in Q2 2026, selling an estimated $5.95M and leaving 30,636 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Schroder Investment Management Group first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. The position peaked at $8.6M in Q3 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Schroder Investment Management Group held 30,636 shares of Apogee Therapeutics worth $4.06M as of Q2 2026.
Schroder Investment Management Group sold 66,020 Apogee Therapeutics shares in Q2 2026, an estimated $5.95M.
Apogee Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #816 holding.
Schroder Investment Management Group first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
Schroder Investment Management Group's Apogee Therapeutics position peaked at $8.6M in Q3 2025.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.